WASHINGTON-Ivax Corp. received federal approval for its generic version of the cancer drug Taxol, making possible a less-expensive version of the blockbuster drug. According to the company, distribution of paclitaxel will begin in a matter of weeks. The drug, widely used to treat breast and ovarian cancers, won tentative approval in August. However, because of pending litigation and patent questions, was unable to receive approval. A spokesperson for the company would not comment on the price but stated that generic versions of brand-name drugs typically cost 30% less. Taxol costs about $7,000 for each course of treatment, but the amount varies depending upon the condition. For more information visit www.ivax.com.
The Sterile Processing Conference Survival Guide: How to Make the Most of Your Next Event
March 25th 2025From expert speakers to cutting-edge tools, sterile processing conferences, like the 2025 HSPA Annual Conference and the SoCal SPA's Spring Conference, offer unmatched opportunities to grow your skills, expand your network, and strengthen your department's infection prevention game.
Redefining Material Compatibility in Sterilization: Insights From AAMI TIR17:2024
March 24th 2025AAMI TIR17:2024 provides updated, evidence-based guidance on material compatibility with sterilization modalities. It offers essential insights for medical device design and ensures safety without compromising functionality.
Unraveling a Candida auris Outbreak: Infection Control Challenges in a Burn ICU
March 19th 2025A Candida auris outbreak in a burn intensive care unit (BICU) in Illinois has highlighted the persistent challenges of infection control in high-risk health care settings. Despite rigorous containment efforts, this multidrug-resistant fungal pathogen continued to spread, underscoring the need for enhanced prevention strategies, environmental monitoring, and genomic surveillance.